Sareum Holdings plc (AIM: SAR)

Market Cap	33.68M
Revenue (ttm)	n/a
Net Income (ttm)	-3.42M
Shares Out	124.75M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,387
Open	27.50
Previous Close	27.00
Day's Range	26.52 - 27.50
52-Week Range	10.00 - 78.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SAR